Data gathered: January 24
AI Stock Analysis - Catalyst Pharmaceuticals (CPRX)
Analysis generated January 15, 2025. Powered by Chat GPT.
Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare and ultra-rare diseases. The company's flagship product is Firdapse, a treatment for Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disorder. Catalyst Pharmaceuticals' mission is to develop and deliver novel drugs that address critical unmet medical needs and improve the quality of life for patients.
Stock Alerts - Catalyst Pharmaceuticals (CPRX)
 |
Catalyst Pharmaceuticals | January 10 Price is down by -5.7% in the last 24h. |
|
Catalyst Pharmaceuticals | January 8 Price is up by 18.6% in the last 24h. |
|
Catalyst Pharmaceuticals | January 6 Price is down by -5.3% in the last 24h. |
|
Catalyst Pharmaceuticals | December 12 Insider Alert: Miller Steve is selling shares |
Alternative Data for Catalyst Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 1 | Sign up | Sign up | Sign up |
| Sentiment | 93 | Sign up | Sign up | Sign up |
| Webpage traffic | 6,000 | Sign up | Sign up | Sign up |
| Employee Rating | 80 | Sign up | Sign up | Sign up |
| Google Trends | 19 | Sign up | Sign up | Sign up |
| Patents | 2 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 5 | Sign up | Sign up | Sign up |
| Facebook Followers | 2,865 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 2 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 15,702 | Sign up | Sign up | Sign up |
| Twitter Followers | 838 | Sign up | Sign up | Sign up |
| Twitter Mentions | 16 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| ESG | 39 | Sign up | Sign up | Sign up |
| Business Outlook | 100 | Sign up | Sign up | Sign up |
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. The company is engaged in the development and commercialization of therapies for people with rare debilitating diseases, chronic neuromuscular and neurological diseases.
| Price | $22.55 |
| Target Price | Sign up |
| Volume | 644,160 |
| Market Cap | $2.73B |
| Year Range | $14.97 - $23.93 |
| Dividend Yield | 0% |
| PE Ratio | 19.38 |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2025 List of America's Most Successful Mid-Cap CompaniesJanuary 23 - GlobeNewswire |
|
 |
Catalyst Pharmaceuticals (NASDAQ:CPRX) Reports FIRDAPSE® Launch in Japan by Sub-Licensee DyDo PharmaOn January 21, 2025, Catalyst Pharmaceuticals, Inc. announced through an 8-K filing that its sub-licensee in Japan, DyDo Pharma, Inc., has initiated tJanuary 22 - ETF Daily News |
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE in JapanJanuary 21 - Finnhub |
|
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE® in JapanJanuary 21 - GlobeNewswire |
|
|
Catalyst Pharmaceuticals Posts Corporate Presentation in Recent 8-K FilingJanuary 20 - ETF Daily News |
Transcript : Catalyst Pharmaceuticals, Inc. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-16-2025 10January 15 - Finnhub |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 129M | 65M | 64M | 44M | 60M | 0.350 |
| Q2 '24 | 123M | 56M | 67M | 41M | 64M | 0.330 |
| Q1 '24 | 99M | 69M | 30M | 23M | 36M | 0.190 |
| Q4 '23 | 111M | 67M | 44M | 35M | 51M | 0.310 |
| Q3 '23 | 103M | 48M | 55M | -31M | -29M | -0.290 |
Insider Transactions View All
| Miller Steve filed to sell 686,996 shares at $21.9. December 11 '24 |
| INGENITO GARY filed to sell 51,391 shares at $22.7. November 29 '24 |
| INGENITO GARY filed to sell 54,760 shares at $22.7. November 29 '24 |
| Elsbernd Brian filed to sell 171,177 shares at $21.6. November 29 '24 |
Similar companies
Read more about Catalyst Pharmaceuticals (CPRX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews & business outlook.
What is the Market Cap of Catalyst Pharmaceuticals?
The Market Cap of Catalyst Pharmaceuticals is $2.73B.
What is Catalyst Pharmaceuticals' PE Ratio?
As of today, Catalyst Pharmaceuticals' PE (Price to Earnings) ratio is 19.38.
What is the current stock price of Catalyst Pharmaceuticals?
Currently, the price of one share of Catalyst Pharmaceuticals stock is $22.55.
How can I analyze the CPRX stock price chart for investment decisions?
The CPRX stock price chart above provides a comprehensive visual representation of Catalyst Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Catalyst Pharmaceuticals shares. Our platform offers an up-to-date CPRX stock price chart, along with technical data analysis and alternative data insights.
Does CPRX offer dividends to its shareholders?
As of our latest update, Catalyst Pharmaceuticals (CPRX) does not offer dividends to its shareholders. Investors interested in Catalyst Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Catalyst Pharmaceuticals?
Some of the similar stocks of Catalyst Pharmaceuticals are Amgen, Gilead Sciences, Inovio Pharmaceuticals, Anavex Life Sciences, and BridgeBio Pharma.
.